Center for Cancer Experimental Therapeutics

癌症实验治疗中心

• 批准号: 8474797
• 负责人: BARBARA N TIMMERMANN
• 金额: $ 105.45万
• 依托单位: UNIVERSITY OF KANSAS LAWRENCE
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-09-01 至 2015-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8474797
• 关键词: Accounting; Affinity; Area; Award; Basic Cancer Research; Biochemical; Biology; Books; Cancer Center; Cells; Centers of Research Excellence; Cities; Collaborations; Complex; Data; Drug Compounding; Educational workshop; Ensure; Funding; Goals; Grant; Housing; Human Resources; Journals; Kansas; Label; Laboratories; Malignant Neoplasms; Manuscripts; Mentors; Mission; Pharmaceutical Chemistry; Phase; Pilot Projects; Program Research Project Grants; Publishing; Request for Applications; Research; Research Personnel; Research Project Grants; Research Support; Services; Small Interfering RNA; Therapeutic; United States National Institutes of Health; Universities; Work; analog; anticancer research; base; design; drug discovery; experience; high throughput screening; indexing; instrumentation; meetings; novel; professor; programs; screening; square foot; structural biology; tool

In this application we are requesting funds to continue our COBRE Center for Cancer Experimental Therapeutics (CCET) for five more years. Our center was among the first group of COBRE grants awarded in 2000. The mission of the CCET is to increase cancer-related research and NIH funding in the State of Kansas. It has been a very successful program (http://ccet.cobre.ku.edu/index.php). During the first ten years of the program our center has funded 26 full Project Awards and 27 smaller First Awards. Thirty tenure track assistant professors have received funding. Of these, 11 have been promoted with tenure and 12 are still on the tenure track. The CCET investigators have obtained 42 NIH-funded grants (17 R01s) and 37 grants from other agencies, leading to a total of about $36,500,000 in new funding to Kansas. These investigators have published 218 journal and book manuscripts on research supported by the CCET. An essential part of our COBRE program was the establishment of two research cores, a High Throughput Screening (HTS) Core and a Medicinal Chemistry (MDC) Core. The COBRE Cores are located in the Structural Biology Center (SBC) located on the University of Kansas West Campus. The modern 4,500 sq.ft. High Throughput Screening Core research/office complex is fully equipped with state-of-the-art instrumentation and the personnel have extensive experience in executing cell-based, biochemical, label-free, siRNA as well as high content screening campaigns. The primary goal of the HTS Core has been to make modern drug discovery tools available to biomedical researchers in the Greater Kansas City area, Kansas and beyond. The equally modern Medicinal Chemistry Core is housed in a laboratory of approximately 2000 square feet. The MDC Core works in conjunction with the HTS Core and in collaboration with COBRE investigators and other researchers. The tasks of the MDC Core are (1) to perform synthesis of known compounds necessary for biochemical studies, (2) to design and synthesize novel drug compounds as probes for ongoing studies, (3) to work with the HTS Core and its biology collaborators in carrying out optimization of hits obtained in screening campaigns, and (4) to synthesize fluorescent or affinity tagged analogs of existing probes when necessary for cell localization or target identification studies. In this Phase III application we are requesting funds to continue these successful research cores and to make them self-sustaining by the end of the five-year funding. In addition, we seek funding to support a Pilot Project program to help basic cancer research investigators obtain preliminary data to strengthen their applications to agencies for major funding. We plan to fund four projects per year. Finally, we request support for an Administrative Core to oversee the entire program, including the Pilot Project program and the two research cores.

在此申请中，我们要求资金继续我们的COBRE癌症实验治疗中心（CCET）五年以上。我们的中心是2000年获得COBRE赠款的第一批中心之一。CCET的使命是增加堪萨斯州与癌症相关的研究和NIH的资金。这是一个非常成功的方案（http：//ccet.cobre.ku.edu/index.php）。在该计划的前十年，我们中心资助了26个完整的项目奖和27个较小的一等奖。30名终身制助理教授获得了资助。其中11人已获得终身职，12人仍在终身职轨道上。CCET研究人员已经获得了42个NIH资助的赠款（17个R 01）和37个来自其他机构的赠款，为堪萨斯提供了总计约3650万美元的新资金。这些研究人员已经发表了218篇关于CCET支持的研究的期刊和书籍手稿。 我们的COBRE计划的一个重要组成部分是建立两个研究核心，一个高通量筛选（HTS）核心和一个药物化学（MDC）核心。COBRE核心位于堪萨斯大学西校区的结构生物学中心（SBC）。现代化的4，500平方英尺核心研究/办公大楼配备了最先进的仪器，工作人员在执行基于细胞的、生化的、无标记的、siRNA以及高含量筛选活动方面具有丰富的经验。HTS核心的主要目标是为大堪萨斯城地区、堪萨斯及其他地区的生物医学研究人员提供现代药物发现工具。 同样现代化的药物化学核心位于一个约2000平方英尺的实验室中。MDC核心与HTS核心一起工作，并与COBRE调查人员和其他研究人员合作。MDC核心的任务是（1）进行生物化学研究所需的已知化合物的合成，（2）设计和合成新的药物化合物作为正在进行的研究的探针，（3）与HTS核心及其生物学合作者合作，对筛选活动中获得的命中进行优化，和（4）当细胞定位或靶鉴定研究需要时，合成现有探针的荧光或亲和标记的类似物。在第三阶段的申请中，我们正在申请资金，以继续这些成功的研究核心，并使他们在五年资助结束时自我维持。此外，我们寻求资金支持试点项目计划，以帮助基础癌症研究调查人员获得初步数据，以加强他们的申请机构的主要资金。我们计划每年资助四个项目。最后，我们请求支持一个行政核心，以监督整个计划，包括试点项目计划和两个研究核心。